Camrelizumab + SOX (oxaliplatin + Teggio) /XELOX (oxaliplatin + capecitabine )
Phase 2UNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 31/100
31
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Locally Advanced Gastric Cancer
Conditions
Locally Advanced Gastric Cancer
Trial Timeline
Sep 20, 2022 → Jun 1, 2023
NCT ID
NCT05545436About Camrelizumab + SOX (oxaliplatin + Teggio) /XELOX (oxaliplatin + capecitabine )
Camrelizumab + SOX (oxaliplatin + Teggio) /XELOX (oxaliplatin + capecitabine ) is a phase 2 stage product being developed by Sun Pharmaceutical for Locally Advanced Gastric Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT05545436. Target conditions include Locally Advanced Gastric Cancer.
What happened to similar drugs?
5 of 20 similar drugs in Locally Advanced Gastric Cancer were approved
Approved (5) Terminated (1) Active (14)
Hype Score Breakdown
Clinical
12
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05545436 | Phase 2 | UNKNOWN |
Competing Products
20 competing products in Locally Advanced Gastric Cancer